U.S. Markets open in 9 hrs 3 mins

Aurinia Pharmaceuticals Inc. (AUPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.18+0.18 (+1.29%)
At close: 4:00PM EDT

Aurinia Pharmaceuticals Inc.

4464 Markham Street
Suite 1203
Victoria V8Z 7X8

Full Time Employees62

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter S. Greenleaf M.B.A.Pres, CEO & Director1.06MN/A1970
Dr. Erik R. Eglite J.D., M.B.A., D.P.M.Sr. VP, Gen. Counsel & Chief Corp. Compliance Officer527.42kN/A1965
Mr. Dennis Bourgeault CPA, C.A.Advisor396.35kN/AN/A
Dr. Neil Solomons M.D.Chief Medical Officer548.85kN/AN/A
Mr. Matthew Maxwell Donley M.B.A.Exec. VP of Internal Operations & Strategy544.83kN/A1969
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.

Corporate Governance

Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of December 8, 2019 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.